Puma regains China rights to Nerlynx and amends deal with Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Partners of the Pierre Fabre Group: from health to beauty
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology | Evaluate
Blue March: Pierre Fabre supports colorectal cancer awareness month
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
THE FACES OF BREAST CANCER
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
